SCHEMBL18608352

SCHEMBL18608352

Cc1ccn2c(=O)c(C(=O)NC3CCCc4ccccc43)cnc2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.55
TAS1R3 Q7RTX0 6/20 0.55
TAS1R1 Q7RTX1 6/20 0.55
TAS1R2 Q8TE23 6/20 0.55
KDM4E B2RXH2 2/20 0.54
SPR P35270 1/20 0.53
ALDH1A1 P00352 3/20 0.52
HSD17B10 Q99714 1/20 0.52
GAA P10253 1/20 0.51
PKM P14618 1/20 0.51
MAPT P10636 1/20 0.51
TSHR P16473 1/20 0.51
USP2 O75604 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C19 P33261 1/20 0.51
HTT P42858 1/20 0.51
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18608347 0.81 TAS1R3 (0.57) LMNATAS1R3TAS1R1TAS1R2KDM4E
SCHEMBL18608561 0.81 ALDH1A1 (0.53) LMNAKDM4EALDH1A1GAAPKM
SCHEMBL9130281 0.80 ALDH1A1 (0.62) KDM4EALDH1A1GAAPKMMAPT
SCHEMBL18608724 0.79 ALDH1A1 (0.56) LMNATAS1R3TAS1R1TAS1R2KDM4E
SCHEMBL18608551 0.75 PDE2A (0.55) LMNATAS1R3TAS1R1TAS1R2KDM4E
SCHEMBL20337349 0.75 ALDH1A1 (0.58) LMNATAS1R3TAS1R1TAS1R2KDM4E
SCHEMBL17743122 0.75 ALDH1A1 (0.58) LMNATAS1R3TAS1R1TAS1R2KDM4E
SCHEMBL19555629 0.74 KDM4E (0.59) LMNATAS1R3TAS1R1TAS1R2KDM4E
SCHEMBL19579149 0.74 KDM4E (0.59) LMNATAS1R3TAS1R1TAS1R2KDM4E
SCHEMBL18608253 0.74 ALDH1A1 (0.62) LMNATAS1R3TAS1R1TAS1R2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190112316-A1 THIAZOLO[3,2-A] PYRIMIDINONE AND OTHER HETEROBICYCLIC PYRIMIDINONE COMPOUNDS FOR USE IN MEDICAL THERAPY LYSOSOMAL THERAPEUTICS INC (US) 2019-04-18 US disclosed
WO-2017040879-A1 THIAZOLO(3,2-A) PYRIMIDINONE AND OTHER HETEROBICYCLIC PYRIMIDINONE COMPOUNDS FOR USE IN MEDICAL THERAPY LYSOSOMAL THERAPEUTICS INC. (US) 2017-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190112316-A1 THIAZOLO[3,2-A] PYRIMIDINONE AND OTHER HETEROBICYCLIC PYRIMIDINONE COMPOUNDS FOR USE IN MEDICAL THERAPY PARK7, GAA, TYMP LMNA 1702/4885TAS1R3 953/4885TAS1R1 926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.